AntiviralGeneral AntiviralPositive observation
Record detail Table 1: CPS-3 EC50/IC50 2.3 ± 0.4 µM (EMSA).
- Measure
- EC50
- Value
- 2.3 ± 0.4 µM (EMSA)
- Target
- SARS-CoV-2
- Assay
- Not reported by source
Back to Evidence
Paper-scoped peptide mentionSequence not reported or unresolved
CPS-3
PMC10668963::PEP000007
Source publication
Unwinding the SARS-CoV-2 Ribosomal Frameshifting Pseudoknot with LNA and G-Clamp-Modified Phosphorothioate Oligonucleotides Inhibits Viral Replication
Biomolecules · 2023
- Sequence status
- not reported or unresolved
- Standardization
- Sequence unresolved
- Source location
- unknown
- Activity records
- 3
Sequence evidence
Reported molecular identity
The publication reports a peptide label or compound identity, but no sequence could be safely standardized from the available text, table, figure, or structure context.
Table 1: CPS-3 EC50/IC50 2.3 ± 0.4 µM (EMSA).
Experimental observations
Records linked to this mention
AntiviralGeneral AntiviralPositive observation
Record detail Section 3.3: 'The IC50 values were equal to ... 30 ± 10 nM (CPS-3)' in HEK-293T-ACE2 cells.
- Measure
- other
- Value
- 30 ± 10 nM
- Target
- HEK-293T-ACE2
- Assay
- Not reported by source
AntiviralGeneral AntiviralPositive observation
Record detail Section 3.3: 'The IC50 values were equal to ... 4 ± 3 nM (CPE-3)' in GBM6138 cells. Note: text says CPE-3 but context indicates CPS-3.
- Measure
- other
- Value
- 4 ± 3 nM
- Target
- GBM6138
- Assay
- Not reported by source
Local peptide labels such as P1, PEP1, or peptide 1 are grouped only within this paper and are not assumed to represent the same molecule across publications.